Featured Research

from universities, journals, and other organizations

Percutaneous Valve Therapy: Is It Safe And Effective?

Date:
October 23, 2007
Source:
Cardiovascular Research Foundation
Summary:
Three new studies evaluate a rapidly advancing field within interventional cardiology: percutaneous procedures to repair and replace defective heart valves. Percutaneous valve procedures, which are currently approved only in Europe, are under study in the US. In particular, researchers are studying the safety and effectiveness of the devices being used and the techniques used to implant them, as well as the profile of patients who should receive them.

Researchers at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation (CRF), presented new studies evaluating a rapidly advancing field within interventional cardiology: percutaneous procedures to repair and replace defective heart valves.

Percutaneous valve procedures, which are currently approved only in Europe, are under study in the U.S. In particular, researchers are studying the safety and effectiveness of the devices being used and the techniques used to implant them, as well as the profile of patients who should receive them.

Several studies analyzing the safety and efficacy of percutaneous valve therapies will be presented at TCT 2007:

High-risk patients receive life-saving valve replacement

In a study of 85 patients at high-risk for surgery with stenotic aortic valves, scientists led by John Webb, MD, FACP(C) and Sanjeevan Pasupati, MBChB, FRACP of St. Paul's Hospital, Vancouver, BC, Canada, describe the first-in-man implantations of the transarterial Percutaneous Aortic Valve (PAV). In these patients, transarterial PAV implantation produced clinical improvements that were sustained at 1 year.

Aortic valve replacement

A team led by Susheel Kodali, MD, of Columbia University, New York, NY, reported mid-term results from the U.S. transcather aortic valve replacement experience. Between December 2005 and November 2006, 55 patients were enrolled. The team concluded that in high-surgical-risk patients, percutaneous aortic valve replacement provides sustained symptom improvement for at least 6-12 months. One-year survival (72.8%) was limited primarily by pre-existing conditions unrelated to the valve implant in this high-risk population.

Successful left ventricle remodeling with new percutaneous valve device

Mitral insufficiency (abnormal blood leakage from the left ventricle through the mitral valve into the left atrium), when severe, may lead to progressive left ventricular enlargement and heart failure. Repair of the leaking mitral valve may improve the function of the failing heart (reverse LV remodeling). A device known as the Mitra Clip was found to be effective, demonstrating significant clinical improvements in patients with mitral regurgitation who had Charlotte, NC.


Story Source:

The above story is based on materials provided by Cardiovascular Research Foundation. Note: Materials may be edited for content and length.


Cite This Page:

Cardiovascular Research Foundation. "Percutaneous Valve Therapy: Is It Safe And Effective?." ScienceDaily. ScienceDaily, 23 October 2007. <www.sciencedaily.com/releases/2007/10/071023104957.htm>.
Cardiovascular Research Foundation. (2007, October 23). Percutaneous Valve Therapy: Is It Safe And Effective?. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/10/071023104957.htm
Cardiovascular Research Foundation. "Percutaneous Valve Therapy: Is It Safe And Effective?." ScienceDaily. www.sciencedaily.com/releases/2007/10/071023104957.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins